Short-term Effect of LDL-Apheresis on Lipid Profile of Patients with Nephrotic and Non-Nephrotic Hyperlipidemia: A Comparative Study
-
Published:2021-04-27
Issue:3
Volume:18
Page:em295
-
ISSN:2516-3507
-
Container-title:Electronic Journal of General Medicine
-
language:
-
Short-container-title:ELECTRON J GEN MED
Author:
Gaipov AbduzhapparORCID,
Nogaibayeva Assem,
Turebekov ZaiyrkhanORCID,
Zharmukhanbet LyazzatORCID,
Orazbayev GaniORCID,
Malykh DmitriyORCID,
Kim NatalyaORCID,
Abbay AnaraORCID,
Tuganbekova Saltanat,
Aljofan MohamadORCID,
Bekishev Bolat
Publisher
Modestum Publishing Ltd
Reference26 articles.
1. Fodor G. Primary Prevention of CVD: Treating Dyslipidemia. Am Fam Physician. 2011;83(10):1207-8.
2. Thompson GR. Management of dyslipidaemia. Heart. 2004;90(8):949-55. https://doi.org/10.1136/hrt.2003.021287
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med. 1996;335(14):1001-9. https://doi.org/10.1056/NEJM199610033351401 PMid:8801446
4. Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol. 2018;14(1):57. https://doi.org/10.1038/nrneph.2017.155 PMid:29176657 PMCid:PMC5770189
5. Wang CS, Greenbaum LA. Nephrotic Syndrome. Pediatr Clin N Am. 2019;66(1):73. https://doi.org/10.1016/j.pcl.2018.08.006 PMid:30454752